Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression : Double-Blind, Randomized Non-Inferiority Trial

Joint Authors

Padula, A. E.
Calil, H. M.
Molina, A.
Adler, U. C.
Paiva, N. M. P.
Adler, M. S.
Cesar, A. T.

Source

Evidence-Based Complementary and Alternative Medicine

Issue

Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-7, 7 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2011-06-08

Country of Publication

Egypt

No. of Pages

7

Main Subjects

Medicine

Abstract EN

Homeopathy is a complementary and integrative medicine used in depression, The aim of this study is to investigate the non-inferiority and tolerability of individualized homeopathic medicines [Quinquagintamillesmial (Q-potencies)] in acute depression, using fluoxetine as active control.

Ninety-one outpatients with moderate to severe depression were assigned to receive an individualized homeopathic medicine or fluoxetine 20 mg day−1 (up to 40 mg day−1) in a prospective, randomized, double-blind double-dummy 8-week, single-center trial.

Primary efficacy measure was the analysis of the mean change in the Montgomery & Åsberg Depression Rating Scale (MADRS) depression scores, using a non-inferiority test with margin of 1.45.

Secondary efficacy outcomes were response and remission rates.

Tolerability was assessed with the side effect rating scale of the Scandinavian Society of Psychopharmacology.

Mean MADRS scores differences were not significant at the 4th (P = .654) and 8th weeks (P = .965) of treatment.

Non-inferiority of homeopathy was indicated because the upper limit of the confidence interval (CI) for mean difference in MADRS change was less than the non-inferiority margin: mean differences (homeopathy-fluoxetine) were −3.04 (95% CI −6.95, 0.86) and −2.4 (95% CI −6.05, 0.77) at 4th and 8th week, respectively.

There were no significant differences between the percentages of response or remission rates in both groups.

Tolerability: there were no significant differences between the side effects rates, although a higher percentage of patients treated with fluoxetine reported troublesome side effects and there was a trend toward greater treatment interruption for adverse effects in the fluoxetine group.

This study illustrates the feasibility of randomized controlled double-blind trials of homeopathy in depression and indicates the non-inferiority of individualized homeopathic Q-potencies as compared to fluoxetine in acute treatment of outpatients with moderate to severe depression.

American Psychological Association (APA)

Adler, U. C.& Paiva, N. M. P.& Cesar, A. T.& Adler, M. S.& Molina, A.& Padula, A. E.…[et al.]. 2011. Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression : Double-Blind, Randomized Non-Inferiority Trial. Evidence-Based Complementary and Alternative Medicine،Vol. 2011, no. 2011, pp.1-7.
https://search.emarefa.net/detail/BIM-478231

Modern Language Association (MLA)

Adler, U. C.…[et al.]. Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression : Double-Blind, Randomized Non-Inferiority Trial. Evidence-Based Complementary and Alternative Medicine No. 2011 (2011), pp.1-7.
https://search.emarefa.net/detail/BIM-478231

American Medical Association (AMA)

Adler, U. C.& Paiva, N. M. P.& Cesar, A. T.& Adler, M. S.& Molina, A.& Padula, A. E.…[et al.]. Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression : Double-Blind, Randomized Non-Inferiority Trial. Evidence-Based Complementary and Alternative Medicine. 2011. Vol. 2011, no. 2011, pp.1-7.
https://search.emarefa.net/detail/BIM-478231

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-478231